Amgen may have crushed Wall Street’s Q3 forecast, but if you didn’t listen to its quarterly conference call, then you probably missed out on these key points concerning its long-term outlook.
Amgen may have crushed Wall Street’s Q3 forecast, but if you didn’t listen to its quarterly conference call, then you probably missed out on these key points concerning its long-term outlook.